Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

AZD0901 i deltagare med avancerade solida tumörer som uttrycker Claudin18.2

28 september 2026 uppdaterad av: AstraZeneca

En fas II, öppen, multicenterstudie för att utvärdera säkerhet, tolerabilitet, effekt, farmakokinetik och immunogenicitet av AZD0901 som monoterapi och i kombination med anticancermedel hos deltagare med avancerade solida tumörer som uttrycker Claudin 18.2.

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .

Studieöversikt

Detaljerad beskrivning

This open-label, multi-centre study consists of individual sub studies, each evaluating the safety and tolerability of AZD0901.

Sub study 1 will investigate the safety, tolerability, and anti-tumour activity of AZD0901 monotherapy in participants with advanced or metastatic gastric esophageal cancer expressing CLDN18.2. Participants will receive AZD0901 monotherapy via intravenous (IV) infusion and will be randomised in to one of 2 arms.

Sub study 2 will consist of two parts, a safety run-in and a dose expansion part to investigate the safety and efficacy of AZD0901 in combination with different chemotherapy agents in participants with pancreatic cancer. Substudy 3 will investigate the safety, tolerability, and anti-tumour activity of AZD0901 monotherapy in participants with advanced or metastatic Biliary tract cancer.

Studietyp

Interventionell

Inskrivning (Beräknad)

226

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Melbourne, Australien, 3000
        • Rekrytering
        • Research Site
      • Murdoch, Australien, WA6150
        • Rekrytering
        • Research Site
      • Randwick, Australien, 2031
        • Rekrytering
        • Research Site
    • California
      • Orange, California, Förenta staterna, 92868
        • Rekrytering
        • Research Site
      • Palo Alto, California, Förenta staterna, 94304
        • Rekrytering
        • Research Site
      • Santa Rosa, California, Förenta staterna, 95403
        • Rekrytering
        • Research Site
    • Kentucky
      • Louisville, Kentucky, Förenta staterna, 40202
        • Rekrytering
        • Research Site
    • New York
      • Commack, New York, Förenta staterna, 11725
        • Rekrytering
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02903
        • Rekrytering
        • Research Site
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • Research Site
      • Tbilisi, Georgien, 0112
        • Rekrytering
        • Research Site
      • Chūōku, Japan, 104-0045
        • Rekrytering
        • Research Site
      • Kashiwa, Japan, 227-8577
        • Rekrytering
        • Research Site
      • Kitaadachi-gun, Japan, 362-0806
        • Rekrytering
        • Research Site
      • Kōtoku, Japan, 135-8550
        • Rekrytering
        • Research Site
      • Nagoya, Japan, 464-8681
        • Rekrytering
        • Research Site
      • Osakasayama-shi, Japan, 589-8511
        • Rekrytering
        • Research Site
    • Ontario
      • Kingston, Ontario, Kanada, K7L 2V7
        • Indragen
        • Research Site
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrytering
        • Research Site
    • Quebec
      • Montreal, Quebec, Kanada, H3G 1A4
        • Rekrytering
        • Research Site
      • Sherbrooke, Quebec, Kanada, J1G 2E8
        • Rekrytering
        • Research Site
      • Changsha, Kina, 410013
        • Har inte rekryterat ännu
        • Research Site
      • Chengdu, Kina, 610041
        • Har inte rekryterat ännu
        • Research Site
      • George Town, Malaysia, 10450
        • Rekrytering
        • Research Site
      • Johor Bahru, Malaysia, 81100
        • Avslutad
        • Research Site
      • Kuala Lumpur, Malaysia, 59100
        • Rekrytering
        • Research Site
      • Kuala Selangor, Malaysia, 62250
        • Rekrytering
        • Research Site
      • Kuching, Malaysia, 93586
        • Rekrytering
        • Research Site
      • Chisinau, Mögel, MD-2025
        • Rekrytering
        • Research Site
      • Krakow, Polen, 31-501
        • Rekrytering
        • Research Site
      • Warsaw, Polen, 02-034
        • Rekrytering
        • Research Site
      • Bukit Merah, Singapore, 169610
        • Rekrytering
        • Research Site
      • Singapore, Singapore, 308433
        • Rekrytering
        • Research Site
      • Singapore, Singapore, 119074
        • Rekrytering
        • Research Site
      • Singapore, Singapore, 329563
        • Rekrytering
        • Research Site
      • Barcelona, Spanien, 08035
        • Rekrytering
        • Research Site
      • Madrid, Spanien, 28007
        • Rekrytering
        • Research Site
      • Madrid, Spanien, 28040
        • Rekrytering
        • Research Site
      • Glasgow, Storbritannien, G12 0YN
        • Indragen
        • Research Site
      • Leeds, Storbritannien, LS9 7TF
        • Indragen
        • Research Site
      • London, Storbritannien, NW3 2QG
        • Indragen
        • Research Site
      • Oxford, Storbritannien, OX3 7LE
        • Indragen
        • Research Site
      • Gyeonggi-do, Sydkorea, 13620
        • Rekrytering
        • Research Site
      • Seoul, Sydkorea, 03080
        • Rekrytering
        • Research Site
      • Seoul, Sydkorea, 06351
        • Rekrytering
        • Research Site
      • Seoul, Sydkorea, 05505
        • Rekrytering
        • Research Site
      • Seoul, Sydkorea, 03722
        • Rekrytering
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Rekrytering
        • Research Site
      • Taichung, Taiwan, 404
        • Rekrytering
        • Research Site
      • Tainan, Taiwan, 70403
        • Rekrytering
        • Research Site
      • Taipei, Taiwan, 11217
        • Rekrytering
        • Research Site
      • Taoyuan, Taiwan, 00333
        • Rekrytering
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

The list below is a summarised eligibility criteria for the study - refer to the study protocol for full criteria.

Master Inclusion Criteria applicable to all sub studies:

  • Participant must be ≥ 18 years or the legal age of consent at the time of signing the ICF.
  • Participants who are CLDN18.2 positive.
  • Must have at least one measurable lesion according to RECIST v1.1.
  • ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing.
  • Predicted life expectancy of ≥ 12 weeks.
  • Adequate organ and bone marrow function as defined by protocol.
  • Body weight > 35 kg.
  • Participants are willing to comply with contraception requirements.

Sub study 1 Specific Inclusion criteria:

  • Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.
  • Advanced or metastatic GC/GEJC.
  • Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.

Sub study 2 Specific Inclusion criteria:

  • Participants diagnosed with histologically confirmed metastatic or advanced PDAC.
  • Availability of an archival sample or a fresh tumour biopsy taken at screening.
  • No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant chemotherapy is permitted as long as participants progressed ≥ 6 months (183 days) from the last dose.

Sub study 3 Specific Inclusion criteria

  • Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma (NOTE: Ampullary cancers are not eligible).
  • Documented radiographic or clinical disease progression on or after at least one prior regimen and maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.

Master Exclusion Criteria applicable to all sub studies:

  • Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
  • Participants with clinically significant ascites that require drainage.
  • A history of drug-induced non-infectious ILD/pneumonitis.
  • Central nervous system metastases or CNS pathology.
  • Peripheral neuropathy, sensory, or motor ≥ Grade 2 at screening.
  • History of another primary malignancy.
  • Prior exposure to any MMAE-based ADC.
  • Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody.

Sub study 1 Specific Exclusion criteria:

  • Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not eligible for standard anti-HER2 therapy, where available.
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
  • The use of concomitant medications known to prolong the QT/QTc interval.

Sub study 2 Specific Exclusion criteria:

  • Known DPD enzyme deficiency based on local testing where testing is SoC.
  • Use of strong inhibitor or inducer of UGT1A1.
  • Use of strong inhibitors or inducers of CYP3A4.
  • Known homozygous for the UGT1A1*28 allele based on local testing where testing is SoC.

Sub study 3 Specific Exclusion criteria

• Clinically significant biliary obstruction that has not resolved before enrollment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Sub Study 1 - AZD0901 MONOTHERAPY

Sub Study 1 will investigate AZD0901 monotherapy in order to evaluate the safety, tolerability, and efficacy of AZD0901.

Antibody-drug conjugate/Biologic

Andra namn:
  • CMG901
Experimentell: Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS IN PANCREATIC DUCTAL ADENOCARCINOMA

Substudy 2 will investigate the safety and efficacy of AZD0901 as first line systemic treatment used in combination with different chemotherapy agents

Antibody-drug conjugate/Biologic

Andra namn:
  • CMG901

Chemotherapy agents

Andra namn:
  • 5-FU

Chemotherapy agents

Andra namn:
  • LV

Chemotherapy agents

Andra namn:
  • I-LV

Chemotherapy agents

Andra namn:
  • Camptosar

Chemotherapy agents

Andra namn:
  • ONIVYDE

Chemotherapy agents

Andra namn:
  • Gemzar
Experimentell: Sub Study 3: AZD0901 MONOTHERAPY IN BILIARY TRACT CANCER

Substudy 3 Further evaluate the preliminary anti-tumour activity of AZD0901 monotherapy by assessment of DRR.

Antibody-drug conjugate/Biologic

Andra namn:
  • CMG901

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
Tidsram: 30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.

To investigate the safety and tolerability, of AZD0901 monotherapy or in combination with anti-cancer agents in particpants with advanced or metastatic solid tumours expressing CLDN18.2.

30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
Objective Response Rate (ORR).
Tidsram: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).

Proportion of participants with a confirmed Complete Response (CR) or Partial Response (PR) as determined by the Investigator at local site as per RECIST v1.1.

From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Survival (OS)
Tidsram: From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).

The analysis will include all dosed/randomised participants as assigned/randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.

From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).
Progression Free Survival (PFS)
Tidsram: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).

Progression-free survival is defined as the time date of randomisation or enrollment until progression per RECIST v1.1 as assessed by the Investigator at local site, or death due to any cause, regardless of whether the participant withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression.

From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).
Duration of Response (DoR)
Tidsram: From the date of first documented confirmed response until date of documented progression (approximately 2 years).

The time from the date of first documented confirmed response until date of first documented progression per RECIST v1.1 or death due to any cause.

From the date of first documented confirmed response until date of documented progression (approximately 2 years).
Disease control rate (DCR)
Tidsram: Up to 11 weeks post date of first dose/randomisation

The percentage of participants who have a confirmed CR or PR or who have SD per RECIST v1.1 as assessed by the Investigator at local site and derived from the raw tumour data up to 11 weeks after date of first dose/randomisation.

Up to 11 weeks post date of first dose/randomisation
Percentage change in tumor size
Tidsram: From start through to study completion.

The best percentage change from baseline in tumor size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST v1.1 assessments.

From start through to study completion.
Serum concentration of AZD0901 (total ADC), total antibody (conjugated and unconjugated) and total unconjugated MMAE
Tidsram: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.

To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2.

From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
Serum PK parameters of AZD0901, total antibody (conjugated and unconjugated) and MMAE including but not limited to AUC, Cmax, tmax, clearance and half-life, as data allow.
Tidsram: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.

To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2.

From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
Clinical activity by baseline and/or on-treatment tissue-based biomarkers including, but not limited to, gene expression, mutation profiles, DNA damage, protein expression, immune response and/or mechanisms of resistance.
Tidsram: From date of first dose of AZD0901 up to 7 weeks.

To investigate baseline and/or on-treatment tissue-based RNA, DNA, and/or proteins, and association with clinical activity of AZD0901 (substudy 1).

From date of first dose of AZD0901 up to 7 weeks.
ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established.
Tidsram: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.

To determine the immunogenicity of AZD0901 monotherapy or in combination with anti-cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2.

From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 december 2023

Primärt slutförande (Beräknad)

17 november 2026

Avslutad studie (Beräknad)

28 juni 2027

Studieregistreringsdatum

Först inskickad

21 november 2023

Först inskickad som uppfyllde QC-kriterierna

12 januari 2024

Första postat (Faktisk)

23 januari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Tidsram för IPD-delning

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Kriterier för IPD Sharing Access

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera